New Genetic Factors Involved in Sudden Unexpected Death in Children
|
By LabMedica International staff writers Posted on 29 Apr 2021 |

Image: New genetic factors involved in Sudden Unexpected Death in Pediatrics (SUDP) have been revealed by combining exome sequencing analysis with detailed phenotyping (Photo courtesy of Boston Children`s Hospital)
About 10% of deaths in infants and children occur suddenly and have no apparent cause. Sudden Unexpected Death in Pediatrics (SUDP) encompasses several related phenomena, including Sudden Infant Death Syndrome (SIDS), Sudden Unexplained Death in Childhood (SUDC), and Sudden Unexpected Infant Death (SUID).
The most widely accepted explanation for these unexplained deaths, is that children with an intrinsic, or genetic, predisposition experience some sort of extrinsic risk, such as soft bedding or a certain sleep position, during a critical period of their development. A new study has found several genes with functions in neurological disease or systemic/syndromic conditions that had not previously been implicated in the SUDP.
Medical Scientists at the Boston Children's Hospital (Boston, MA, USA) and their colleagues surveyed a total of 352 SUDP cases, including 73 with parental samples. The age of death in these children ranged from one day to 11 years, with an average of six months, and the team obtained detailed phenotypic descriptions for them. The investigators conducted exome sequencing and analyzed the data for rare damaging variants in genes involved in neurological, cardiac, and systemic or syndromic disease mechanisms, a list of 294 potential SUDP genes. They classified variants as pathogenic, likely pathogenic, and variants of uncertain significance (VUS) and introduced an additional category, called VUS-favor pathogenic (VUS-FP).
In a proband-only analysis, they identified 109 rare damaging variants in 98 probands, or 28% of which 12 were classified as pathogenic or likely pathogenic and 17 as VUS-FP. This was a higher burden of such variants than in healthy controls. In addition, an analysis of the parent-proband exome data uncovered 51 de novo variants, of which eight were classified as pathogenic/likely pathogenic or VUS-FP, as well as 13 X-linked maternally inherited variants. A burden analysis found that SUDP trios had almost three times more rare damaging de novo variants than controls, suggesting that these variants play a causal role.
Overall, the scientists identified 38 rare damaging variants, 16 pathogenic or likely pathogenic and 22 VUS-FP variants in the SUDP cases, accounting for 11% of all cases. Of those, 14 were in neurological, 18 in cardiac, and six in systemic/syndromic disease genes. Variants in cardiac disease genes all occurred in children who died within their first year of life.
The authors concluded that their results suggest that genetic factors play an important role in SUDP. The findings can provide bereaved parents with an explanation of why their child died, help identify at-risk family members, and lead to counseling about recurrence risk. The study was presented at the American College of Medical Genetics and Genomics annual clinical meeting held virtually on 13-16 April, 2021.
Related Links:
Boston Children's Hospital
The most widely accepted explanation for these unexplained deaths, is that children with an intrinsic, or genetic, predisposition experience some sort of extrinsic risk, such as soft bedding or a certain sleep position, during a critical period of their development. A new study has found several genes with functions in neurological disease or systemic/syndromic conditions that had not previously been implicated in the SUDP.
Medical Scientists at the Boston Children's Hospital (Boston, MA, USA) and their colleagues surveyed a total of 352 SUDP cases, including 73 with parental samples. The age of death in these children ranged from one day to 11 years, with an average of six months, and the team obtained detailed phenotypic descriptions for them. The investigators conducted exome sequencing and analyzed the data for rare damaging variants in genes involved in neurological, cardiac, and systemic or syndromic disease mechanisms, a list of 294 potential SUDP genes. They classified variants as pathogenic, likely pathogenic, and variants of uncertain significance (VUS) and introduced an additional category, called VUS-favor pathogenic (VUS-FP).
In a proband-only analysis, they identified 109 rare damaging variants in 98 probands, or 28% of which 12 were classified as pathogenic or likely pathogenic and 17 as VUS-FP. This was a higher burden of such variants than in healthy controls. In addition, an analysis of the parent-proband exome data uncovered 51 de novo variants, of which eight were classified as pathogenic/likely pathogenic or VUS-FP, as well as 13 X-linked maternally inherited variants. A burden analysis found that SUDP trios had almost three times more rare damaging de novo variants than controls, suggesting that these variants play a causal role.
Overall, the scientists identified 38 rare damaging variants, 16 pathogenic or likely pathogenic and 22 VUS-FP variants in the SUDP cases, accounting for 11% of all cases. Of those, 14 were in neurological, 18 in cardiac, and six in systemic/syndromic disease genes. Variants in cardiac disease genes all occurred in children who died within their first year of life.
The authors concluded that their results suggest that genetic factors play an important role in SUDP. The findings can provide bereaved parents with an explanation of why their child died, help identify at-risk family members, and lead to counseling about recurrence risk. The study was presented at the American College of Medical Genetics and Genomics annual clinical meeting held virtually on 13-16 April, 2021.
Related Links:
Boston Children's Hospital
Latest Pathology News
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read moreIndustry
view channel








